Skip to main content

Biotechnology Value Fund L P's Form 4 filing

POINT Biopharma Global Inc. (PNT) · filed Dec 20, 2023

Accession no.
0001193805-23-001635
Filed
Dec 20, 2023, 6:09 PM ET
Trade date
Dec 18, 2023
Filing delay
2 days
Rule 10b5-1 plan
Not checked

This filing lists 3 non-derivative transactions. Open-market sales total $213.7M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Biotechnology Value Fund L PCIK 0000918923Other: Former 10% Owner
BVF Partners L PCIK 0001055947Other: Former 10% Owner
BVF IncCIK 0001056807Other: Former 10% Owner
Biotechnology Value Fund II LPCIK 0001102444Other: Former 10% Owner
Lampert Mark NCIK 0001233840Other: Former 10% Owner
Biotechnology Value Trading Fund OS LPCIK 0001660683Other: Former 10% Owner
BVF Partners OS Ltd.CIK 0001660684Other: Former 10% Owner
BVF I GP LLCCIK 0001803805Other: Former 10% Owner
BVF II GP LLCCIK 0001803806Other: Former 10% Owner
BVF GP Holdings LLCCIK 0001803809Other: Former 10% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Dec 18, 2023Common Stock, $0.0001 par valueSSaleDisposed−8,974,245$12.45−$111,729,350.250Direct
Dec 18, 2023Common Stock, $0.0001 par valueSSaleDisposed−7,290,667$12.45−$90,768,804.150Direct
Dec 18, 2023Common Stock, $0.0001 par valueSSaleDisposed−896,366$12.45−$11,159,756.70Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

No transaction price on this filing refers to a footnote.

Read the full filing on SEC EDGAR (opens in a new tab)